Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAN6 versus SHAN5 pentavalent/hexavalent vaccine schedules in healthy Kenyan infants
PACTR202006580901172Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of DTwP-HepB-Hib-IPV hexavalent vaccine, DTwP-HepB-Hib vaccine, bivalent oral poliovirus vaccine and inactivated poliovirus vaccine in diphtheria, Tetanus, pertussis and 4 more (6 arms), sponsored by Sanofi. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
DTwP-HepB-Hib-IPV hexavalent vaccineDTwP-HepB-Hib vaccinebivalent oral poliovirus vaccineinactivated poliovirus vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on PACTR202006580901172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006580901172.